Diffuse Large B-Cell Lymphoma (ASCO) Basic Listing

Updates in Diffuse Large B-Cell Lymphoma

From the ASCO Annual Meeting

Conference Coverage

Evaluating the Efficacy of Odronextamab Plus CHOP vs R-CHOP Among Patients With Previously Untreated DLBCL

06/11/2024

Featuring Matthew Matasar, MD

Matthew Matasar, MD, discusses ongoing data from the phase 3 OLYMPIA-3 trial which examines odronextamab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) versus rituximab plus CHOP among patients with previously...

Matthew Matasar, MD, discusses...

06/11/2024

Oncology

Videos

Novel Updates in DLBCL and MCL Treatment Research From the 2024 ASCO Meeting

06/04/2024

Featuring John Burke, MD

John Burke, MD, discusses some of the most compelling topics in diffuse large B-cell lymphoma and mantle cell lymphoma research presented at the 2024 ASCO Annual Meeting.

John Burke, MD, discusses some...

06/04/2024

Oncology

David Andorsky, MD, Rocky Mountain Cancer Centers

Conference Coverage

Subcutaneous Epcoritamab Demonstrated Efficacy Among Patients With R/R DLBCL and FL Treated in the Outpatient Setting

06/03/2024

Featuring David Andorsky, MD

David Andorsky, MD, discussed results from the phase 2 EPCORE NHL-6 trial, which showed that patients with R/R DLBCL and FL who were treated with subcutaneous epcoritamab demonstrated positive results in the outpatient setting.

David Andorsky, MD, discussed...

06/03/2024

Oncology

Videos

Frontline Treatment With Epcoritamab Plus R-CHOP for Patients With High-Risk DLBCL

06/19/2023

Lorenzo Falchi, MD presents updated EPCORE NHL-2 data on epcoritamab combined with R-CHOP for the treatment of patients with high-risk diffuse large B-cell lymphoma.

Lorenzo Falchi, MD presents...

06/19/2023

Oncology

Videos

Glofitamab Monotherapy for Patients With R/R Diffuse Large B-Cell Lymphoma

06/13/2023

Lorenzo Falchi, MD presents extended follow-up from a pivotal phase 2 study on CD20-CD3 bispecific antibody glofitamab monotherapy for patients with R/R DLBCL.

Lorenzo Falchi, MD presents...

06/13/2023

Oncology

Videos

Split-Dose R-CHOP Treatment for Older Patients With Diffuse Large B-Cell Lymphoma

06/07/2023

At the 2023 American Society of Clinical Oncology Annual Meeting, Nirav Niranjan Shah, MD, shared findings from a phase 2 trial of split-dose R-CHOP for older patients with DLBCL.

At the 2023 American Society of...

06/07/2023

Oncology

Conference Coverage

R-CHP Plus Polatuzumab Vedotin Regimen Improved Progression-Free Survival Compared to R-CHOP Among Elderly Patients With DLBCL

06/02/2023

Jordan Kadish ;

Findings from a phase 3 trial indicated that a polatuzumab vedotin and R-CHP regimen significantly improved the progression-free survival among elderly patients with diffuse large B-cell lymphoma compared to an R-CHOP regimen.

Findings from a phase 3 trial...

06/02/2023

Oncology

Conference Coverage

Combination Treatment Yielded Durable Remissions Among Patients With DLBCL Variant of Richter Syndrome

06/02/2023

Jordan Kadish ;

Findings from the phase 2 MOLTO trial indicated that atezolizumab, obinutuzumab, and venetoclax combination treatment yielded durable remissions among patients with untreated DLBCL variant of Richter syndrome.

Findings from the phase 2 MOLTO...

06/02/2023

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology